Genentech Exec Heads East To Take The Reins Of Cancer-Focused Start-up Agios
This article was originally published in The Pink Sheet Daily
Executive Summary
Calling it “the right time and the right opportunity,” Genentech’s cancer drug development expert David Schenkein plans to move on.
You may also be interested in...
Celgene Expands Agios Collaboration In Cancer Metabolism
Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.
Celgene Expands Agios Collaboration In Cancer Metabolism
Cancer metabolism specialist Agios extends research collaboration with Celgene, picking up an additional $20 million.
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators